Pipeline
Committed to the Discovery, Development, and Commercialization of Potentially Transformational Therapies
As Amylin continues to expand opportunities for its commercialized products in the near term, the company's mid and long-term R&D programs support a robust product development pipeline, primarily focused on innovative new therapies for diabetes and obesity. These are investigational products and are not approved by the FDA.
- A once weekly formulation of exenatide is in late stage clinical investigation for the treatment of type 2 diabetes. Clinical trial results have been released highlighting improvements in glycemic control, complemented by weight loss.
- Another potentially transformational therapy in development is a unique combination of pramlintide and metreleptin, a product candidate of Amylin's Integrated Neurohormonal Therapy for Obesity (INTO) program. INTO is a novel investigational approach designed to harness the naturally occurring power of peptide and protein hormones and apply them in combination to improve patient outcomes in the struggle for weight loss.
